AddLife (ALIF-B.ST) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals SEK Explore free reports

AddLife (ALIF-B.ST) overview

AddLife (ALIF-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, AddLife reported revenue of SEK 10,442m and operating profit of SEK 780m; the year-end share price was 159.10 SEK and market capitalisation was SEK 19,389m. AddLife is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AddLife's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 5,443mFY 2025
Share price159.10 SEKFY 2025 year end
RevenueSEK 10,442mFY 2025
Operating profitSEK 780mFY 2025
Net earningsSEK 562mFY 2025
Market capitalisationSEK 19,389mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About AddLife

AddLife AB is a Swedish life science company active mainly in Europe. It owns and develops niche subsidiaries in two business areas, Labtech and Medtech, supplying products, solutions and services for healthcare, laboratories and research. Its offering includes medical technology, diagnostics, laboratory instruments, advisory services, product service and training.

Generate the AddLife report

AddLife is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AddLife and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AddLife

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.